GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation October 25, 2024Vol.50 No.40By Jacquelyn Cobb
NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials October 25, 2024Vol.50 No.40By Claire Marie Porter
FreeGuest Editorial Evaluation of cancer care in Ukraine shows good access to treatment despite wartimeWork remains to be done to ensure high-quality care October 25, 2024Vol.50 No.40By Taras Ivanykovych, Darya Kizub, Marta Antoniv, Inesa Huivaniuk, Anna Uzlova, Marta Naumova, Andrei Nikiforchin and Nelya Melnitchouk
Cancer History ProjectFree Susan Ellenberg started out as a high school math teacher—then became a leading biostatistician October 25, 2024Vol.50 No.40By McKenzie Prillaman
Climate change exacerbates cancer disparitiesAmid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem October 18, 2024Vol.50 No.39By Claire Marie Porter
ACS board member Wayne Frederick steps in as interim CEO, replacing Karen KnudsenNational search will be conducted October 18, 2024Vol.50 No.39By Paul Goldberg
Is nivolumab superior to standard of care for classic Hodgkin lymphoma?Phase III trial finds improved PFS, side effects with nivolumab+chemo October 18, 2024Vol.50 No.39By McKenzie Prillaman
Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer October 18, 2024Vol.50 No.39By Jacquelyn Cobb
How the 2024 elections can impact cancer policy October 18, 2024Vol.50 No.39By Samyukta Mullangi and Debra Patt
